An Jusheng,Zhang Yunyan,Feng Mei, et al. A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)-positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed [J].JOURNAL OF CLINICAL ONCOLOGY,2023,41(16).